Use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker

US10983136B2 · kind B2 · utility

Assignee

• DIASORIN S.p.A. · IT

Inventors

• Francesco Colotta · L'Aquila, IT
• Fabrizio Bonelli · Alessandria, IT
• Frank Blocki · Chaska, US
• Claudia Zierold · Windom, US
• Joshua Caine Soldo · Burnsville, US
• Gregory Olson · Plano, US
• Michael Lutterman · New Brighton, US
• John Wall · Limerick, IE
• Michael New · Bloomington, US
• Hector F. DeLuca · Deerfield, US

Key dates

• Filing date: Jul 17, 2017
• Grant date: Apr 20, 2021
• Expiry date: Dec 28, 2037

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/60
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

The present invention relates to the use of 1,25-dihydroxyvitamin D values in ratio with PTH as a prognostic biomarker. More particularly, the present invention relates to a method for predicting or stratifying the risk of worsening renal function (WRF) in a patient at risk of renal injury or affected by renal injury. Levels of 1,25-dihydroxyvitamin D (1,25(OH)2D) are measured in a biological sample and taken together with parathyroid hormone (PTH) levels to provide a ratio indicative of the risk of worsening renal function.